OncLive SOSS

Optimizing Therapy for Endometrial Cancer: Recent Data Highlights - Episode 6

Treatment Choices for Recurrent dMMR Endometrial Cancer

November 13, 2023

Ritu Salani, MD, Bhavana Pothuri, MD

Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.

Video Player is loading.

Current Time 0:00

Duration 6:18

Loaded: 0%

Stream Type LIVE

Remaining Time 6:18

EP. 1: Changing Landscape of Endometrial Cancer: Incidence and Classification

EP. 2: Optimal Workup Strategies in Advanced Endometrial Cancer

EP. 3: Factors in Frontline Treatment Decision Making for Endometrial Cancer

EP. 4: Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors

EP. 5: Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy

EP. 6: Treatment Choices for Recurrent dMMR Endometrial Cancer

EP. 7: HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment

EP. 8: Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab

EP. 9: Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab

EP. 10: Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status

EP. 11: Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy

EP. 12: Diversity and Access to Clinical Trials in Endometrial Cancer

x